Viral and Non-viral Vectors
Viral and non-viral vectors are crucial gene delivery vehicles for cell and gene therapies, yet they are difficult to manufacture to a scale that meets the growing demand. Across vector characterization, raw materials and supply chain, there are many limitations and obstacles to consider.
In April 2020, we conducted a survey of cell and gene therapy professionals all over the world, to find out what difficulties they were experiencing, and which areas were in the greatest need of innovation.
Based on over 100 responses, the following report provides insight into the biggest opportunities and challenges surrounding viral and non-viral vector manufacturing which are ready to be addressed.
Click on any of the graphics in this report to explore the data further.
Representatives from biotech companies made up the majority of participants with 39% and medical device companies/regulatory agencies were the lowest.
VP/Head/Directors were the most popular job titles for this survey with 33% whilst investor and research were the least popular job titles.
The majority of participants of this survey were based in North America at 48% and 35% of participants were from Europe.
Over 52% of the companies that participated in the survey focus on oncology. Rare diseases is also a popular area of focus.
Gene therapy and CAR-T are the main focus areas or are in the pipeline for the participants of this survey.
Over 37% of our participants are in Phase I of their cell or gene therapy clinical trials and another 33% of the participants are in Phase II.
What are the main vectors types you are working with?
When considering raw and starting materials used in viral vector manufacturing where are the biggest limitations?
As the demand for vectors in the space grows, where do you think the biggest changes need to be made with regards to current manufacturing platforms? (Selected responses)
Irrespective of which method you are currently using which of the below do you think non-viral has the potential to address?